Literature DB >> 3567515

Carcinoma of the head of the pancreas: bypass surgery in unresectable disease.

G La Ferla, W R Murray.   

Abstract

One hundred patients who underwent bypass surgery for unresectable, histologically proven carcinoma of the head of the pancreas were studied to determine: the incidence of a second operation for duodenal obstruction in survivors who had a biliary diversion only; whether the addition of a prophylactic gastroenterostomy is associated with increased mortality. Eighty-six patients (Group A) had a biliary diversion alone while fourteen (Group B) had a biliary diversion and a prophylactic gastroenterostomy. Both groups were comparable regarding sex, age, symptomatology and clinical findings. The postoperative mortality was similar for both groups (Group A, 27.9 per cent; Group B, 14.3 per cent). The mean surgically related hospital stay was 22 +/- 6.5 days (Group A) and 20 +/- 7 days (Group B). Of the 62 patients in Group A who left hospital, 8 (13 per cent) required a second operation for duodenal obstruction (mean interval 5.4 +/- 2.7 months). The in-hospital stay for the second operation was 14.4 +/- 7.7 days. The overall survival for both groups was identical at 6 months (35.5 versus 33.3 per cent) and 12 months (19.3 versus 16.7 per cent). This study suggests that prophylactic gastroenterostomy adds no risk to patients requiring biliary diversion for carcinoma of the head of the pancreas. Its routine use is therefore justified since 13 per cent of the patients who survived the biliary diversion required further surgery for duodenal obstruction before death.

Entities:  

Mesh:

Year:  1987        PMID: 3567515     DOI: 10.1002/bjs.1800740321

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  12 in total

1.  Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice.

Authors:  J R Andersen; S M Sørensen; A Kruse; M Rokkjaer; P Matzen
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

2.  Surgery offers the best palliation for carcinoma of the pancreas.

Authors:  I S Bailey; J Keating; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1991-07       Impact factor: 1.891

Review 3.  Biliary and gastric bypass or stenting in nonresectable periampullary cancer: analysis on the basis of controlled trials.

Authors:  A Schwarz; H G Beger
Journal:  Int J Pancreatol       Date:  2000-02

4.  Morbidity and mortality after radical and palliative pancreatic cancer surgery. Risk factors influencing the short-term results.

Authors:  K E Bakkevold; B Kambestad
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

5.  Should endoscopic stenting be the initial treatment of malignant biliary obstruction?

Authors:  J J Earnshaw; J P Hayter; C Teasdale; D E Beckly
Journal:  Ann R Coll Surg Engl       Date:  1992-09       Impact factor: 1.891

6.  Risk factors for morbidity and mortality following gastroenterostomy.

Authors:  Martin Poulsen; Mauro Trezza; Ghayyath H Atimash; Lars T Sorensen; Finn Kallehave; Ulla Hemmingsen; Lars N Jorgensen
Journal:  J Gastrointest Surg       Date:  2009-04-28       Impact factor: 3.452

7.  'Cross-section gastroenterostomy' in patients with irresectable periampullary carcinoma.

Authors:  O Horstmann; C W Kley; S Post; H Becker
Journal:  HPB (Oxford)       Date:  2001       Impact factor: 3.647

Review 8.  Cystic duct patency in malignant obstructive jaundice. An ERCP-based study relevant to the role of laparoscopic cholecystojejunostomy.

Authors:  P R Tarnasky; R E England; L M Lail; T N Pappas; P B Cotton
Journal:  Ann Surg       Date:  1995-03       Impact factor: 12.969

9.  Biliary bypass and palliation for pancreatic cancer.

Authors:  C D Johnson
Journal:  J R Soc Med       Date:  1990-08       Impact factor: 18.000

10.  Simultaneous Duodenal Metal Stent Placement and EUS-Guided Choledochoduodenostomy for Unresectable Pancreatic Cancer.

Authors:  Kazumichi Kawakubo; Hiroyuki Isayama; Yousuke Nakai; Naoki Sasahira; Hirofumi Kogure; Takashi Sasaki; Kenji Hirano; Minoru Tada; Kazuhiko Koike
Journal:  Gut Liver       Date:  2012-07-12       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.